http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2012531925-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-118 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B25-10 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N37-00 |
| filingDate | 2009-10-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2012-12-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2012531925-A |
| titleOfInvention | Tibozanib response prediction |
| abstract | Disclosed is a diagnostic method for quantitatively predicting whether a human tumor is responsive or resistant (non-responsive) to treatment with the VEGF inhibitor tivozanib (AV-951) . The test is based on the application of an algorithm to measure the expression level of genes in the predicted gene set. Predicted gene sets are AIF1, APBB1IP, ARGGAP30, C3AR1, CCR1, CD37, CD53, CD86, CLEC7A, CSF1R, CSF2RB, CTSS, CYBB, DOCK2, EVI2A, EVI2B, FPR3, GMFG, GPR65, HCK, LA , IL10RA, ITGB2, LAIR1, LCP1, LCP2, LILRB1, LILRB2, LST1, LY86, MNDA, MS4A6A, MYO1F, NCF4, SLA, SLAMF8, TLR1, TYROBP, PLEK, CYTH4, and PTPRC. |
| priorityDate | 2009-07-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 454.